Milestones in the pathogenesis and management of primary liver cancer

Jean Charles Nault; Ann Lii Cheng; Bruno Sangro; Josep M. Llovet

doi:10.1016/j.jhep.2019.11.006

Milestones in the pathogenesis and management of primary liver cancer

Jean Charles Nault, Ann Lii Cheng, Bruno Sangro, Josep M. Llovet

Research output: Contribution to journal › Editorial

32 Scopus citations

Original language	English
Pages (from-to)	209-214
Number of pages	6
Journal	Journal of Hepatology
Volume	72
Issue number	2
DOIs	https://doi.org/10.1016/j.jhep.2019.11.006
State	Published - Feb 2020

Access to Document

10.1016/j.jhep.2019.11.006

Cite this

@article{1e8a3808cece4ba597e4fe71d2d6e0f3,

title = "Milestones in the pathogenesis and management of primary liver cancer",

author = "Nault, {Jean Charles} and Cheng, {Ann Lii} and Bruno Sangro and Llovet, {Josep M.}",

note = "Funding Information: Josep M. Llovet is supported by National Cancer Institute ( P30-CA196521 ), U.S. Department of Defense ( CA150272P3 ), European Commission / Horizon 2020 Program (HEPCAR, Ref. 667273-2 ), EIT Health (CRISH2, Ref. 18053), Accelerator Award ( CRUCK , AECC , AIRC ) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation , Spanish National Health Institute ( SAF2016-76390 ) and the Generalitat de Catalunya / AGAUR ( SGR-1358 ). Funding Information: Josep M. Llovet is supported by National Cancer Institute (P30-CA196521), U.S. Department of Defense (CA150272P3), European Commission/Horizon 2020 Program (HEPCAR, Ref. 667273-2), EIT Health (CRISH2, Ref. 18053), Accelerator Award (CRUCK, AECC, AIRC) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and the Generalitat de Catalunya/AGAUR (SGR-1358).JC Nault declared no conflict of interests related with this topic. Ann-Lii Cheng has received consulting or lecture fees from Bayer HealthCare Pharmaceuticals Inc., Eisai, Bayer Yakuhin, Ltd., Merck Sharp & Dohme, Eisai, Merck Serono, Novartis, Ono Pharmaceutical, Exelixis, Nucleix Ltd., Roche/Genentech, Bristol-Myers Squibb, Shanghai Hengrui Pharmaceutical Co., Ltd., and IQVIA. Bruno Sangro has received consulting or lecture fees from Adaptimmune, Astra Zeneca, Bayer, BMS, BTG, H3 Biomedicine, Ipsen, Lilly, Merck, Onxeo, Roche/Genentech, Sirtex Medical, and Terumo; and research grants from BMS, Onxeo, and Sirtex Medical. Josep M Llovet is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb and Ipsen, and consulting fees from Bayer HealthCare Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Eisai Inc, Merck, Celsion Corporation, Exelixis, Ipsen, Glycotest, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech, Sprink Pharmaceuticals, Nucleix and Can-Fite.",

year = "2020",

month = feb,

doi = "10.1016/j.jhep.2019.11.006",

language = "English",

volume = "72",

pages = "209--214",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Milestones in the pathogenesis and management of primary liver cancer

AU - Nault, Jean Charles

AU - Cheng, Ann Lii

AU - Sangro, Bruno

AU - Llovet, Josep M.

N1 - Funding Information: Josep M. Llovet is supported by National Cancer Institute ( P30-CA196521 ), U.S. Department of Defense ( CA150272P3 ), European Commission / Horizon 2020 Program (HEPCAR, Ref. 667273-2 ), EIT Health (CRISH2, Ref. 18053), Accelerator Award ( CRUCK , AECC , AIRC ) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation , Spanish National Health Institute ( SAF2016-76390 ) and the Generalitat de Catalunya / AGAUR ( SGR-1358 ). Funding Information: Josep M. Llovet is supported by National Cancer Institute (P30-CA196521), U.S. Department of Defense (CA150272P3), European Commission/Horizon 2020 Program (HEPCAR, Ref. 667273-2), EIT Health (CRISH2, Ref. 18053), Accelerator Award (CRUCK, AECC, AIRC) (HUNTER, Ref. C9380/A26813), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and the Generalitat de Catalunya/AGAUR (SGR-1358).JC Nault declared no conflict of interests related with this topic. Ann-Lii Cheng has received consulting or lecture fees from Bayer HealthCare Pharmaceuticals Inc., Eisai, Bayer Yakuhin, Ltd., Merck Sharp & Dohme, Eisai, Merck Serono, Novartis, Ono Pharmaceutical, Exelixis, Nucleix Ltd., Roche/Genentech, Bristol-Myers Squibb, Shanghai Hengrui Pharmaceutical Co., Ltd., and IQVIA. Bruno Sangro has received consulting or lecture fees from Adaptimmune, Astra Zeneca, Bayer, BMS, BTG, H3 Biomedicine, Ipsen, Lilly, Merck, Onxeo, Roche/Genentech, Sirtex Medical, and Terumo; and research grants from BMS, Onxeo, and Sirtex Medical. Josep M Llovet is receiving research support from Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb and Ipsen, and consulting fees from Bayer HealthCare Pharmaceuticals, Eli Lilly, Bristol-Myers Squibb, Eisai Inc, Merck, Celsion Corporation, Exelixis, Ipsen, Glycotest, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech, Sprink Pharmaceuticals, Nucleix and Can-Fite.

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85076531556&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2019.11.006

DO - 10.1016/j.jhep.2019.11.006

M3 - Editorial

C2 - 31954486

AN - SCOPUS:85076531556

SN - 0168-8278

VL - 72

SP - 209

EP - 214

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 2

ER -